Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q3 2019 Earnings Presentation
29 slides from Orion Oyj Class A's earnings presentation, Oct 23, 2019
Slide 1: Orion Interim Report 1–9/2019
Orion Interim Report 1–9/2019
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January–September 2019
Highlights in January–September 2019
Slide 4: Marketing authorisation for darolutamide in the USA – application review ongoing in other main markets
Marketing authorisation for darolutamide in the USA – application review ongoing in other main markets 1 Marketing authorisation granted for darolutamide in the USA. Application review ongoing in 3 Easyhaler® and Simdax® showing strong performance. Specialty Products’ net sales Europe, Japan and oth
Slide 5: Key figures 1−9/2019
Key figures 1−9/2019 Net sales Operating profit Operating profit Cash flow per share margin before financial items* 776 198 25% 1.28 MEUR (715) MEUR (184) (26%) EUR (2.10) +9% +7% -39% *) Comparison period cash flow per share before financial items includes both continuing and discontinued operation
Slide 6: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 4 776 37 -2 -18 4 15 11 37 -9 198 13 -10 715 -5 184 3 -5 * Product sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix chan
Slide 7: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-9/2019 MEUR 1-9/2019 1-9/2018 11% 300 +12% 29% -2% 250 11% 200 150 +14% -21% +108% 100 32% 17% 50 0 Finland Scandinavia Other Europe North America ROW Interim Report 1–9/2019 © Orion Corporation 23 October 2019
Slide 8: Growth in all business divisions
Growth in all business divisions 1−9/2019 1−9/2018 1-9/2019 MEUR +1% 400 +18% 5% 2% 349 347 350 8% 308 300 261 40% 250 +1% 200 150 +11% +14% 45% +3% 100 64 58 43 38 50 13 12 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion CM* & Animal Health Products Products Health ot
Slide 9: Best-selling pharmaceuticals 1–9/2019
Best-selling pharmaceuticals 1–9/2019 Net sales Change vs . Indication (EUR million) 1−9/2018 1. Asthma, COPD 75 +16% 2. Parkinson’s disease 70 -7% 3. Acute heart failure 49 +14% 4. Intensive care sedative 46 -5% Rheumatoid arthritis, inflammatory 5. Biosimilars bowel diseases, lymphoma 28 +47% 6. A
Slide 10: Proprietary Products
Proprietary Products
Slide 11: Easyhaler® product family and Simdax® growing
Easyhaler® product family and Simdax® growing 1-9/2019 +16% -7% MEUR 80 75 76 70 22% 23% 70 64 -5% +14% 60 46 48 49 50 43 16% 40 30 20 24% 10 15% 0 Parkinson Easyhaler® Easyhaler® Parkinson Dexdor® Simdax® franchise Dexdor® Simdax® Other 1−9/2019 1−9/2018 Interim Report 1–9/2019 © Orion Corporation
Slide 12: Easyhaler® product family will be a key source of growth in the next few years
Easyhaler® product family will be a key source of growth in the next few years Sales, EUR million 30 ● Budesonide-formoterol Easyhaler® +23% 25 continued strong growth. 20 ● Product family total sales: +16% 15 10 ● Salmeterol-fluticasone sales developed slower than anticipated. 5 0 ● Development of
Slide 13: Share of Orion's own sales in Parkinson growing
Share of Orion’s own sales in Parkinson growing Sales, EUR million 50 45 40 35 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 2016 2017 2018 2019 Orion's own sales Parkinson (Stalevo®, Comtan®) deliveries to partners Interim Report 1–9/2019 © Orion
Slide 14: Sales of Dexdor® declining due to generic competition
Sales of Dexdor® declining due to generic competition Total value of European sedatives market: Sales, EUR million EUR 585 million (+4%) 20 12% 18 16 14 12% 12 66% 10 8 6 10% 4 2 0 Propofol 383 Meur (+4%) Midazolam 61 Meur (-3%) 2014 2015 2016 2017 2018 2019 Dexmedetomidine 72 Meur (+7%) Remifentani
Slide 15: Specialty Products
Specialty Products GRION Building well-being
Slide 16: Specialty Products: tight price competition continued
Specialty Products: tight price competition continued Development of net sales Net sales by region Net sales by product 1−9/2019 1−9/2019 MEUR -1% 250 10% 8% 199 200 200 14% 25% 150 +27% +2% 57% 100 65 51 48 47 19% 50 67% 0 Finland Scandinavia Eastern Finland Generic drugs Europe and Scandinavia Rus
Slide 17: In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs
In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1–9/2019) in Finland MEUR 319 (342) MEUR 85 (90) Market development Or
Slide 18: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−9/2019 Self-care Medicinal and non-medicinal products Reference priced products in hospital and pharmacy channels: EUR 2,083 million prescription Orion market share in EUR million drugs pharmacy 250 229 Orion 200 137 73 market s
Slide 19: Research and development
Research and development
Slide 20: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targeted FGFR+VEGF
Slide 21: Orion's key business targets in 2019 (1–2)
Orion's key business targets in 2019 1. Preparation for the commercialisation • Marketing authorisation of darolutamide. ARASENS trial (metastatic applications submitted in the main prostate cancer) continues in order to markets. expand the indication for the molecule. • Marketing authorisation gran
Slide 22: Orion's key business targets in 2019 (3–5)
Orion's key business targets in 2019 3. Strengthening Orion’s position as the • Orion's sales volume in Finland most significant provider of generic drugs grew faster than the market. in Finland. Competitive product portfolio in Specialty Products and strengthening of product launches. 4. Accelerati
Slide 23: Disruptions in drug availability a global topic
Disruptions in drug availability a global topic Interim Report 1–9/2019 © Orion Corporation 23 October 2019
Slide 24: In Finland deficiencies concern mainly reference priced prescription drugs
In Finland deficiencies concern mainly reference priced prescription drug Total sales of human pharmaceuticals 1-9/2019 Total volume of human pharmaceuticals (hospital and pharmacy channel) MEUR 2,083 1-9/2019 (hospital and pharmacy channel) ~99 million packages 40% 21% 8% 27% 16% 30% 14% 44% Other
Slide 25: Key themes of corporate responsibility
Key themes of corporate responsibility Availability of Orion products in Finland >96% Responsibility Ensure patient for the environment Ethics and safety and – production according Taking care of transparency of availability of to the principles Orionees operations medicines of sustainable developme
Slide 26: Outlook
Outlook
Slide 27: Outlook for 2019 remains unchanged
Outlook for 2019 remains unchanged Net sales Orion estimates that in 2019 net sales will be slightly higher than in 2018 (net sales in 2018 were EUR 977 million). The estimated net sales include the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide. Oper
Slide 28: Orion calendar
Orion calendar Financial Statement Release for 2019 5/2/2020 AGM planned to be held 25/3/2020 Interim Report 1−3/2020 28/4/2020 Half-Year Report 1−6/2020 17/7/2020 Interim Report 1−9/2020 21/10/2020
Slide 29: Building well-being
Building well-being GRIoN Building well-being